Updated efficacy, safety, and correlative analysis of a phase II trial in metastatic renal cell carcinoma with coordinated pembrolizumab and high dose IL-2.

Authors :: Johnson, Jeffrey S
Fishman, Mayer N
Schell, Michael J
Yu, Xiaoqing
Wang, Xuefeng
Roman Souza, Gabriel
Miller, Justin
Mizelle, Sarah Raymond
Gullapalli, Keerthi
Fazili, Adnan Nazir
Guske, Christopher
Mannam, Gowtam
Jameel, Ghazal
Cen, Ling
Yao, Jiqiang
Whiting, Junmin
Swank, Jennifer
Zhang, Jingsong
Spiess, Philippe E.
Chahoud, Jad
Source :: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p554-554, 177p
Publication Year :: 2025

Full Text Access

Tools